EXV-801

DRUG2 trials

Sponsors

Exciva GmbH

Conditions

Agitation Associated With Alzheimer's Disease DementiaAgitation in Alzheimer's Disease Dementia

Phase 2

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

RecruitingNCT07284472

Exciva GmbHAgitation Associated With Alzheimer's Disease Dementia

Start: 2026-02-02End: 2029-02-01Target: 300Updated: 2026-08-14

Phase 2/3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Participants with Alzheimer’s Disease Dementia

Not yet recruitingCTIS2024-517388-22-00

Exciva GmbHAgitation in Alzheimer's Disease Dementia

Target: 96Updated: 2026-04-29